CU23388B6 - Composición farmacéutica de microesferas para prevenir la amputación del pie diabético - Google Patents

Composición farmacéutica de microesferas para prevenir la amputación del pie diabético

Info

Publication number
CU23388B6
CU23388B6 CU20060021A CU20060021A CU23388B6 CU 23388 B6 CU23388 B6 CU 23388B6 CU 20060021 A CU20060021 A CU 20060021A CU 20060021 A CU20060021 A CU 20060021A CU 23388 B6 CU23388 B6 CU 23388B6
Authority
CU
Cuba
Prior art keywords
pharmaceutical composition
microspheres
diabetic foot
administration
prevent amputation
Prior art date
Application number
CU20060021A
Other languages
English (en)
Inventor
Martinez Vivian Maria Saez
Rodriguez Blas Yamir Betancourt
Hernandez Jose Angel Ramon
Meireles Rolando Paez
Acosta Jorge Amador Berlanga
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38185604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23388(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20060021A priority Critical patent/CU23388B6/es
Priority to PT07702319T priority patent/PT1987817E/pt
Priority to EP07702319A priority patent/EP1987817B1/en
Priority to CNA2007800090345A priority patent/CN101400338A/zh
Priority to ES07702319T priority patent/ES2330688T3/es
Priority to JP2008552668A priority patent/JP5219841B2/ja
Priority to DK07702319T priority patent/DK1987817T3/da
Priority to RU2008135354/15A priority patent/RU2426528C2/ru
Priority to PL07702319T priority patent/PL1987817T3/pl
Priority to BRPI0707395-0A priority patent/BRPI0707395A2/pt
Priority to CN201410189221.8A priority patent/CN103933552A/zh
Priority to US12/162,505 priority patent/US8741848B2/en
Priority to CA2640743A priority patent/CA2640743C/en
Priority to AU2007211753A priority patent/AU2007211753B2/en
Priority to MYPI20082850A priority patent/MY143742A/en
Priority to PCT/CU2007/000002 priority patent/WO2007087759A2/es
Priority to DE602007001786T priority patent/DE602007001786D1/de
Priority to SI200730087T priority patent/SI1987817T1/sl
Priority to KR1020087021210A priority patent/KR101401273B1/ko
Priority to AT07702319T priority patent/ATE437631T1/de
Priority to SG201100715-0A priority patent/SG169366A1/en
Priority to ARP070100377A priority patent/AR059234A1/es
Priority to ZA200806648A priority patent/ZA200806648B/xx
Publication of CU23388B6 publication Critical patent/CU23388B6/es
Priority to CY20091101105T priority patent/CY1109513T1/el
Priority to HK14112245.2A priority patent/HK1198743A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica que contiene microesferas cargadas con Factor de Crecimiento Epidérmico para ser administrada por vía parental en los miembros inferiores de pacientes diabéticos aquejados de lesiones isquémicas cutáneas crónicas. La composición de la presente invención, en contraste al estado de la técnica anterior, es útil porque reduce la frecuencia de administración durante el tratamiento y permite que la cicatrización de las lecciones sea más rápida comparada con la administración de cantidades equivalentes del Factor libre en solución.
CU20060021A 2006-01-31 2006-01-31 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético CU23388B6 (es)

Priority Applications (25)

Application Number Priority Date Filing Date Title
CU20060021A CU23388B6 (es) 2006-01-31 2006-01-31 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
SG201100715-0A SG169366A1 (en) 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic foot amputation
CA2640743A CA2640743C (en) 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic limb amputation
MYPI20082850A MY143742A (en) 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic limb amputation
CNA2007800090345A CN101400338A (zh) 2006-01-31 2007-01-29 用于预防糖尿病足截除的微球体药物组合物
ES07702319T ES2330688T3 (es) 2006-01-31 2007-01-29 Composicion farmaceutica de microesferas para prevenir la amputacion de pie diabetico.
JP2008552668A JP5219841B2 (ja) 2006-01-31 2007-01-29 糖尿病の足切断を防止するためのマイクロスフェア医薬組成物
DK07702319T DK1987817T3 (da) 2006-01-31 2007-01-29 Farmaceutisk sammensætning til mikrosfærer til forebyggelse af diabetisk fodamputation
RU2008135354/15A RU2426528C2 (ru) 2006-01-31 2007-01-29 Фармацевтическая композиция в виде микросфер для профилактики ампутации конечностей при диабете
PL07702319T PL1987817T3 (pl) 2006-01-31 2007-01-29 Kompozycja farmaceutyczna mikrosfer do zapobiegania amputacji stopy cukrzycowej
BRPI0707395-0A BRPI0707395A2 (pt) 2006-01-31 2007-01-29 uso de uma composição farmacêutica que contém microesferas de fator de crescimento epidérmico
CN201410189221.8A CN103933552A (zh) 2006-01-31 2007-01-29 用于预防糖尿病足截除的微球体药物组合物
US12/162,505 US8741848B2 (en) 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic foot amputation
PT07702319T PT1987817E (pt) 2006-01-31 2007-01-29 Composição farmacêutica de microesferas para prevenir a amputação do pé diabético
AU2007211753A AU2007211753B2 (en) 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic foot amputation
EP07702319A EP1987817B1 (en) 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic foot amputation
PCT/CU2007/000002 WO2007087759A2 (es) 2006-01-31 2007-01-29 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
DE602007001786T DE602007001786D1 (de) 2006-01-31 2007-01-29 Pharmazeutische zusammensetzung von mikrokügelchen zur verhinderung einer amputation eines diabetischen fusses
SI200730087T SI1987817T1 (sl) 2006-01-31 2007-01-29 Farmacevtski sestavek mikrokroglic za preprečevanje amputacije diabetičnih nog
KR1020087021210A KR101401273B1 (ko) 2006-01-31 2007-01-29 당뇨병성 발 절단을 예방하기 위한 마이크로스피어의 약학적 조성물
AT07702319T ATE437631T1 (de) 2006-01-31 2007-01-29 Pharmazeutische zusammensetzung von mikrokügelchen zur verhinderung einer amputation eines diabetischen fusses
ARP070100377A AR059234A1 (es) 2006-01-31 2007-01-30 Composicion farmaceutica de microesferas para prevenir la amputacion del pie diabetico
ZA200806648A ZA200806648B (en) 2006-01-31 2008-07-30 Pharmaceutical composition of microspheres for preventing diabetic foot amputation
CY20091101105T CY1109513T1 (el) 2006-01-31 2009-10-23 Φαρμακευτικη συνθεση μικροσφαιριδιων για την προληψη του ακρωτηριασμου διαβητικου ποδιου
HK14112245.2A HK1198743A1 (en) 2006-01-31 2014-12-04 Pharmaceutical composition of microspheres for preventing diabetic foot amputation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060021A CU23388B6 (es) 2006-01-31 2006-01-31 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético

Publications (1)

Publication Number Publication Date
CU23388B6 true CU23388B6 (es) 2009-07-16

Family

ID=38185604

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060021A CU23388B6 (es) 2006-01-31 2006-01-31 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético

Country Status (24)

Country Link
US (1) US8741848B2 (es)
EP (1) EP1987817B1 (es)
JP (1) JP5219841B2 (es)
KR (1) KR101401273B1 (es)
CN (2) CN101400338A (es)
AR (1) AR059234A1 (es)
AT (1) ATE437631T1 (es)
AU (1) AU2007211753B2 (es)
BR (1) BRPI0707395A2 (es)
CA (1) CA2640743C (es)
CU (1) CU23388B6 (es)
CY (1) CY1109513T1 (es)
DE (1) DE602007001786D1 (es)
DK (1) DK1987817T3 (es)
ES (1) ES2330688T3 (es)
HK (1) HK1198743A1 (es)
MY (1) MY143742A (es)
PL (1) PL1987817T3 (es)
PT (1) PT1987817E (es)
RU (1) RU2426528C2 (es)
SG (1) SG169366A1 (es)
SI (1) SI1987817T1 (es)
WO (1) WO2007087759A2 (es)
ZA (1) ZA200806648B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
RU2351334C1 (ru) * 2007-12-04 2009-04-10 Георгий Кимович Золоев Способ лечения хронической ишемии нижних конечностей ii б - iv степени
ES2340902B1 (es) 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
KR101156094B1 (ko) * 2010-02-22 2012-06-20 경상대학교산학협력단 약물송달을 위한 양친성 ＰＨＡ－ｍＰＥＧ 공중합 나노 컨테이너
RU2421221C1 (ru) * 2010-03-22 2011-06-20 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения критической ишемии нижних конечностей различного генеза
RU2425675C1 (ru) * 2010-05-25 2011-08-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения больных с нейропатической и нейроишемической формами синдрома "диабетическая стопа"
ES2357601B1 (es) 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
EP2737895A1 (en) 2012-11-30 2014-06-04 Praxis Pharmaceutical, S.A. Microparticles with EGF, method of preparation and use
EP2821077A1 (en) 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing
EP3097922A1 (fr) 2015-05-28 2016-11-30 Denis Barritault Composition pour le traitement des lesions tissulaires
CN106267163A (zh) * 2015-06-09 2017-01-04 济南博创医药科技有限公司 一种治疗皮肤创伤的药物组合物及其药物制剂
MX389934B (es) * 2016-12-09 2025-03-20 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos.
KR102218427B1 (ko) * 2017-09-20 2021-02-22 차의과학대학교 산학협력단 단백질 약물을 포함하는 코아세르베이트 조성물 및 이를 포함하는 창상 치료제
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5034375A (en) 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US4944948A (en) * 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
WO1990011781A1 (en) 1989-04-04 1990-10-18 Alcon Laboratories, Inc. The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
WO1991001719A1 (en) 1989-08-01 1991-02-21 The University Of Michigan Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes
AU629316B2 (en) * 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
AU725654B2 (en) * 1996-05-03 2000-10-19 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
US6193994B1 (en) * 1996-05-23 2001-02-27 Samyang Corporation Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US5861149A (en) * 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
AU2000202A (en) * 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
CU23043A1 (es) * 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
US7517528B2 (en) 2002-03-12 2009-04-14 Bio-Click Technologies, Ltd. Method and composition for treating skin wounds with epidermal growth factor
CN1720989A (zh) 2004-07-15 2006-01-18 深圳市清华源兴生物医药科技有限公司 一种表皮生长因子缓释微球及其制备方法与应用
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético

Also Published As

Publication number Publication date
ATE437631T1 (de) 2009-08-15
DE602007001786D1 (de) 2009-09-10
BRPI0707395A2 (pt) 2011-05-03
CN103933552A (zh) 2014-07-23
WO2007087759A3 (es) 2007-09-20
RU2008135354A (ru) 2010-03-10
ZA200806648B (en) 2009-05-27
CN101400338A (zh) 2009-04-01
SG169366A1 (en) 2011-03-30
HK1198743A1 (en) 2015-06-05
US8741848B2 (en) 2014-06-03
JP5219841B2 (ja) 2013-06-26
JP2009525288A (ja) 2009-07-09
CY1109513T1 (el) 2014-08-13
AU2007211753A1 (en) 2007-08-09
MY143742A (en) 2011-07-15
KR101401273B1 (ko) 2014-05-29
PT1987817E (pt) 2009-10-26
AR059234A1 (es) 2008-03-19
RU2426528C2 (ru) 2011-08-20
KR20080096804A (ko) 2008-11-03
ES2330688T3 (es) 2009-12-14
CA2640743C (en) 2012-05-15
EP1987817A2 (en) 2008-11-05
EP1987817B1 (en) 2009-07-29
WO2007087759A2 (es) 2007-08-09
PL1987817T3 (pl) 2010-01-29
SI1987817T1 (sl) 2009-12-31
CA2640743A1 (en) 2007-08-09
US20090220608A1 (en) 2009-09-03
DK1987817T3 (da) 2009-11-30
AU2007211753B2 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
CU23388B6 (es) Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
ECSP11010809A (es) Derivados de pirazolo[3,4-d]pirimidin-4-il y sus usos en el tratamiento de diabetes y obesidad
RU2013140182A (ru) Композиция гиалуроновой кислоты
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
Tevanov et al. Negative pressure wound therapy (NPWT) to treat complex defect of the leg after electrical burn
EA200900881A1 (ru) Ингаляционные лекарственные формы связанных с полимерами бифосфонатов и способы их применения
EA200971073A1 (ru) Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
ES2615255T3 (es) Uso de compuestos oligosacáridos para la prevención y el tratamiento de cicatrices patológicas
EA201990419A1 (ru) Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение
AR058590A1 (es) Uso topico del factor de crecimiento epidermico en liposomas para prevenir la amputacion del pie diabetico
Álvarez‐Pérez et al. Hair‐thread tourniquet syndrome: a hidden hazard
Martorell-Calatayud et al. Multiple painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea
RU2012100621A (ru) Композиция для инъекций, содержащая гидроксихлорохин, для местного применения при лечении геморроя
Takač et al. Conservative surgical management of necrotic tissues following meningococcal sepsis: case report of a child treated with hyperbaric oxygen
CN104490923B (zh) 愈合膏
NO20061515L (no) Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn
Amouzou et al. Practice of negative pressure wound therapy (NPWT) in Togo
Shaikh et al. Presentation of compartment syndrome without an obvious cause can delay treatment. A case report
CN201049023Y (zh) 医用胶棉纱条
Lozano et al. Vitamin B12 and wound healing: analysis of 2 lesions in the cranial region
Maffulli et al. Letter to the editor to comment on" Endoscopic flexor hallucis longus transfer for acute Achilles tendon ruptures is associated with a high re-rupture rate: A prospective case series"
Bilal Question 1: Does use of a splint increase the functional duration of cannulae in neonates?
Kataria et al. Comparison of the effects of lignocaine, lignocaine plus paracetamol, lignocaine plus tramadol in intravenous regional anesthesia